COMPLEMENT 3 GLOMERULOPATHY (C3G)
Clinical trials for COMPLEMENT 3 GLOMERULOPATHY (C3G) explained in plain language.
Never miss a new study
Get alerted when new COMPLEMENT 3 GLOMERULOPATHY (C3G) trials appear
Sign up with your email to follow new studies for COMPLEMENT 3 GLOMERULOPATHY (C3G), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Matched conditions: COMPLEMENT 3 GLOMERULOPATHY (C3G)
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control APPROVED_FOR_MARKETINGThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Matched conditions: COMPLEMENT 3 GLOMERULOPATHY (C3G)
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC